GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.05 (+0.05%)

Growth Price

Overvalued by 74.92%

Stability Price

Overvalued by 85.92%

Company Metrics

  • 24.36 P/E
  • 9.32 P/S
  • 10.17 P/B
  • 4.414 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0.00 / N/A % Dividend
  • 11.99M Avg. Vol.
  • 162.6B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Has Gilead Sciences, Inc.'s Star Drug Already Peaked?
Motley Fool - Aug 29, 2014
Gilead Sciences' (NASDAQ: GILD ) hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed.
Gilead: Let's Make A Deal - Seeking Alpha (registration)
Should Gilead Sciences, inc. Fear This New Competitor Drug?
Motley Fool - Aug 26, 2014
ViiV hopes that this multi-drug combination can not only improve patient adherence rates, but win away market share from HIV drug treatment leader Gilead Sciences (NASDAQ: GILD ) , which markets some of the most widely prescribed therapies for the ...
A Double Dose of Good News for Gilead Sciences, Inc.
Motley Fool - Aug 15, 2014
Not only has the biotech's hepatitis C treatment Sovaldi become a multibillion-dollar drug less than a year into its launch, but Gilead got two pieces of good news today in the announcements of a positive result from a lawsuit and coverage of Sovaldi ...
The Competition To Gilead's Hepatitis C Drug Sovaldi - Bidness Etc
Gilead wins critical Sovaldi legal fight, Roche finds consolation - MarketWatch (blog)
3 Reasons Gilead Science, Inc.'s Stock Could Rise
Motley Fool - Aug 20, 2014
Sovaldi is a cash cow for Gilead Sciences. In the second quarter alone, Gilead generated $4.2 billion in cash flow from operations.
Gilead Sciences: 'Risk of HCV Price War Overblown,' Bernstein Says - Barron's (blog)
10 S&P 500 companies growing faster than their rivals - MarketWatch
Gilead: Earnings Forecast Justifies $140 Price Target (GILD)
Seeking Alpha (registration) - Aug 26, 2014
I have been recommending Gilead (NASDAQ:GILD) for the past 3 years, and for the past 2 years my price target has been $140.
Strongly Positioned Gilead Reaches 52-Week High
Bidness Etc - Aug 18, 2014
Gilead Sciences, Inc. (GILD) gained around 8% in last week and continued rising in trading today, backed by favorable company news and strong performance of its top drug, Sovaldi.
Gilead Sciences Looks Like A Contrarian Short
Seeking Alpha (registration) - Aug 12, 2014
Impending competition from the companies like AbbVie can hurt Gilead Sciences. At present ... This clearly indicates that a lot of the good news is already priced in and the company has many risks ahead of them, which the market isn't appreciating ...
Time to Focus on Gilead Sciences (GILD) for Strong Earnings Growth Potential -
Gilead Sciences, Inc. (NASDAQ:GILD) Has 19% Upside: Argus - Markets Insider
Gilead Sciences: Due For More Short Squeezing? (GILD)
Seeking Alpha (registration) - Aug 27, 2014
This, for the company that has launched the most successful drug in the history of our planet. Perhaps I am biased, as I am not only long Gilead, but it is the largest holding in my portfolio. But it still surprises me that so many bets against the ...
Why Gilead Sciences (GILD) Could Be Positioned for a Surge? - Aug 29, 2014
Gilead Sciences Inc. (GILD - Analyst Report) is a healthcare company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate ...
Why Gilead Sciences Is Still A Great Investment Opportunity (GILD)
Seeking Alpha (registration) - Aug 4, 2014
Although Gilead Sciences Inc. (NASDAQ:GILD) has significantly outperformed the market since the beginning of 2012, In my opinion, it still has plenty of room to move up.
Government health programs pay billions for Gilead's hepatitis C drug as ... - San Francisco Business Times (blog)
Hepatitis C cure available — but only if you can afford it - Toronto Star